Sangamo Therapeutics (SGMOQ) Total Current Liabilities (2010 - 2025)

Sangamo Therapeutics has reported Total Current Liabilities for 16 years, with the latest figure at $42.5 million in Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 7.29% year-over-year to $42.5 million in Q4 2025; TTM through Dec 2025 was $42.5 million, a 7.29% decrease from a year earlier, with the FY2025 full-year figure at $42.5 million, down 7.29% from the prior year.
• Total Current Liabilities was $42.5 million for Q4 2025 at Sangamo Therapeutics, down from $50.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $136.9 million in Q2 2021, with the low at $39.0 million in Q2 2024.
• Average Total Current Liabilities over 5 years is $78.4 million, with a median of $52.0 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2023: Total Current Liabilities soared 114.03% in 2021, then sank 60.38% in 2023.
• Over 5 years, Total Current Liabilities stood at $127.9 million in 2021, then dropped by 12.65% to $111.7 million in 2022, then tumbled by 57.27% to $47.7 million in 2023, then fell by 4.04% to $45.8 million in 2024, then fell by 7.29% to $42.5 million in 2025.
• The last three Total Current Liabilities figures came in at $42.5 million (Q4 2025), $50.1 million (Q3 2025), and $47.7 million (Q2 2025), per Business Quant data.